Learn more about our project

The new challenges in the XXI century demand a full understanding of the resources we have, how to manage them and how to increase their value.

  • Our motto

    The business of science

  • Our vision

    Apply state of the art science into your business

  • Our purpose

    To enhance your biological assets

Our business model

Our business model is based in 3 leverages


We deliver science to you, wherever remote area you are, with our scientific staff.


We adapt to every project, depending on product, market, environment, legality, and even risk assessment.

Success oriented

We win when the value of your assets increase. We don’t accept all projects, only the ones we believe in. 

Our potencial in a nutshell

1 - Consulting

Tailored to your business needs

We analyse your case and integrate a state-of-the-art biotech strategy for your business needs.

2 - Variability

Studying genetic variation

Determine whether your population segregates enough genetic variation. We can optimize the variability of your bio asset.

3 - Phenotypes

Phenotype stability and variation analysis

We elaborate the appropriate experimental design and study the environmental condi-tions that would make your bio asset reach its maximum potential.

4 - Sequencing

Genome and transcriptome annotation

Sequence and annotate the molecular “instructions” for the species of interest

5 - GWAS

Genome-wide association studies

We sequence a large set of selected individuals and compile the genetic variation that makes them different.

6 - Mapping

Genotype/phenotype map

Integrate GWAS, transcriptome and phenotype variation together to predict the performance of a new variety that would carry selected combinations of genetic variants.

7 - Selective Crosses

Population variation selection

We can scaff old the genetic architecture of interest into a new variety by crossing selected mother lines.

8 - CrispR/Cas9

In vitro

Alternatively, we can create a plant variety that would carry the naturally occurring variants to improve its market value.

If you are interested in participating in any of our projects and have rights over our genomic information and derived products, contact us through our investor deck